SmithKline Beecham Paxil panic disorder and OCD claims approved by FDA.

Executive Summary

SMITHKLINE BEECHAM PAXIL ELIMINATES FULL PANIC ATTACKS IN 76% of patients treated with Paxil 40 mg daily compared to 44% for placebo during a 10-week dose-ranging study, according to labeling for use of Paxil (paroxetine) in panic disorder. SmithKline Beecham's selective serotonin reuptake inhibitor was approved by FDA for the new indications of panic disorder and obsessive-compulsive disorder May 7. Paxil's supplemental NDA for panic disorder was submitted in March 1995. The supplemental NDA for OCD was filed in December 1994.